Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Shamita Shah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ochsner Health, New Orleans, LA, USA. Hauptthemen laut MEDLINE: Healthcare Disparities, Inflammatory Bowel Diseases, Quality of Life. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Scientific Affairs, LLC.
Abstract (Originalsprache)
Background
Data regarding care access and outcomes in Black/Indigenous/People of Color/Hispanic (BIPOC/H) individuals is limited. This study evaluated care barriers, disease status, and outcomes among a diverse population of White/non-Hispanic (W/NH) and BIPOC/H inflammatory bowel disease (IBD) patients at a large U.S. health system.
Methods
An anonymous online survey was administered to adult IBD patients at Ochsner Health treated between Aug 2019 and Dec 2021. Collected data included symptoms, the Consumer Assessment of Healthcare Providers and Systems and Barriers to Care surveys, health-related quality of life (HRQOL) via the Short Inflammatory Bowel Disease Questionnaire, the Medication Adherence Rating Scale-4, and the Beliefs about Medicines Questionnaire. Medical record data examined healthcare resource utilization. Analyses compared W/NH and BIPOC/H via chi-square and t tests.
Results
Compared with their W/NH counterparts, BIPOC/H patients reported more difficulties accessing IBD specialists (26% vs 11%; P = .03), poor symptom control (35% vs 18%; P = .02), lower mean HRQOL (41 ± 14 vs 49 ± 13; P < .001), more negative impact on employment (50% vs 33%; P = .029), worse financial stability (53% vs 32%; P = .006), and more problems finding social/emotional support for IBD (64% vs 37%; P < .001). BIPOC/H patients utilized emergency department services more often (42% vs 22%; P = .004), reported higher concern scores related to IBD medication (17.1 vs 14.9; P = .001), and worried more about medication harm (19.5% vs 17.7%; P = .002). The survey response rate was 14%.
Conclusions
BIPOC/H patients with IBD had worse clinical disease, lower HRQOL scores, had more medication concerns, had less access to specialists, had less social and emotional support, and used emergency department services more often than W/NH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Ochsner Health, New Orleans, LA, USA.
- EPI-Q Inc, Oak Brook, Illinois, USA.
- Research Administration, Penn Medicine Lancaster General Health, Lancaster, PA, USA.
- Prevention Access Campaign, Atlanta, GA, USA.
- Population Health, Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
- Department of Gastroenterology, Morehouse School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Brandon LaChappelle
Förderung
- Janssen Scientific Affairs, LLC
Zitieren
APA
Shah, S., Shillington, A. C., Kabagambe, E. K., Deering, K. L., Babin, S., Capelouto, J., Pulliam, C., Patel, A., LaChappelle, B., & Liu, J. (2024). Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad194
Vancouver
Shah S, Shillington AC, Kabagambe EK, Deering KL, Babin S, Capelouto J, et al. Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad194
BibTeX
@article{Shah2024,
author = {Shah, Shamita and Shillington, Alicia C and Kabagambe, Edmond Kato and Deering, Kathleen L and Babin, Sheena and Capelouto, Joseph and Pulliam, Cedric and Patel, Aarti and LaChappelle, Brandon and Liu, Julia},
title = {Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad194}
}
EUVIMED